Journal of Pharmaceutical Research

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


Dissolution testing has been recognized as an important tool in drug development and assessment of quality of pharmaceutical products both in case of novel drug product and interchangeability drug products. In vitro dissolution testing is one of the primary United States Pharmacopoeia/National Formulary (USP/ NF) test, which is performed to ensure that a drug product meet the USP/NF standards of identity, strength, quality, purity, stability and bioequivalence in case of interchangeable drug products. In vitro dissolution profile comparison of drug release can be used as a surrogate in formulation development and in vivo bioequivalence testing. The comparison of dissolution profiles is considered to be critical test for assessing the performance of a drug product. In the present study, in vitro dissolution profile of two in-house batches, containing Biopharmaceutical Classification System (BCS) class 1 API (Zidovudine) was compared with reference product (Retrovir) by model independent approach to meet the requirements for biowaiver. Batch 2 of in-house formulation is considered to be similar to reference product and could be interchangeable.

Keywords

Biopharmaceutical Classification System, Biowaivers, in Vitro Dissolution Profile Comparison.
User
Notifications
Font Size